Evidence map›Paper›PMID 30341707›Full record

ArticleEndocrine2019

Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy.

Valentina Gasco, Marina Caputo, Valeria Cambria, Guglielmo Beccuti, Mirko Parasiliti Caprino, Ezio Ghigo, Mauro Maccario, Silvia Grottoli

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Valentina GascoDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Science, University of Turin, Turin, Italy. valentina.gasco@unito.it.ORCID 0000-0002-6491-5731
Marina CaputoDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Science, University of Turin, Turin, Italy.
Valeria CambriaDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Science, University of Turin, Turin, Italy.
Guglielmo BeccutiDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Science, University of Turin, Turin, Italy.
Mirko Parasiliti CaprinoDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Science, University of Turin, Turin, Italy.
Ezio GhigoDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Science, University of Turin, Turin, Italy.
Mauro MaccarioDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Science, University of Turin, Turin, Italy.
Silvia GrottoliDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Science, University of Turin, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMost patients treated for hypothalamic-pituitary tumours develop GH deficiency. Long-term GH replacement treatment in adults with a previous history of hypothalamic-pituitary tumour could represent a concern about increasing the risk of tumour enlargement or recurrence. PURPOSE: To assess the progression risk of hypothalamic-pituitary tumours according to the GH secretory status (normal GH secretion, non-treated and treated GH deficiency). and determine the predictors of neoplasm recurrence.

methodsWe retrospectively reviewed 309 patients with tumours of the hypothalamic-pituitary region (294 subjects underwent neurosurgery while 81 radiotherapy) who were followed for 9.9 ± 8.3 years.

resultsOut of 309 patients, 200 were affected by severe GH deficiency; 90 of these underwent GH therapy. The tumour progression rate did not differ among GH-sufficient, not-treated and treated GH-deficient patients (16.5%, 16.4%. and 10.0%, respectively). In a multivariate analysis, previous radiotherapy (HR 0.12, CI 0.03-0.52, p < 0.005) and residual tumour (HR 8.20, CI 2.38-28.29, p < 0.001) were independent predictors of recurrence. After controlling for multiple covariates, the tumour recurrence risk in GH-sufficient and GH-treated patients was similar to that observed in not-treated GH-deficient patients.

conclusionsWith limitations of retrospective analysis, GH therapy is not associated with an increased progression rate of tumours of the hypotalamic-pituitary region during long follow-up, thus supporting the long-term safety of GH treatment. The only predictors of tumour recurrence appear to be the presence of residual disease and the lack of radiotherapy.

Indexed as

AdultAgedDisease ProgressionFemaleFollow-Up StudiesHormone Replacement TherapyHuman Growth HormoneHumansHypothalamic NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalNeurosurgical ProceduresPituitary NeoplasmsRadiotherapyHuman Growth HormoneGH deficiencyGH replacementPituitary tumoursProgressionRecurrence

Identifiers

PMID30341707

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.